Xilio Therapeutics
XLO | NASDAQ
$7.70
-$0.37 (-4.64%)
At close: Nov 16, 2026, 4:00 PM ET
$7.70
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-4.64%
(1D)No price chart data available for 1D timeframe.
Rating
48
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #326/1021 (Top 32%)
Key Statistics
Market Data
Market Cap $151.6M
1D Range
7.10 8.44
52W Range
7.10 11.30
Valuation (TTM)
PE -19.25
PB 2.22
EV/EBITDA -3.48
Valuation (NTM)
Forward PE 1.54
Forward PEG 0.48
Price Target $16.00
Cash Flow
FCF Yield -38.0%
SBC Adj. FCF Yield -43.7%
SBC Impact -15.0%
Margins
Gross Margin 99.4%
Operating Margin -74.9%
FCF Margin -104.8%
Growth (CAGR)
Revenue 3Y | 5Y 82.7% |
77.6%
Dil EPS 3Y | 5Y 101.1% |
49.4%
FCF 3Y | 5Y -64.5% |
19.4%
Returns
ROA -8.5%
ROE -18.5%
ROIC -37.6%
Financial Health
Net Cash
$122.18M
Current Ratio 4.72
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX1...
Sector Healthcare
Industry Biotechnology
Employees 76
IPO Date Oct 22, 2021
Website www.xiliotx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 10, 2026
EPS
-$0.3
Beat +67.91%
YoY:
+80.52% REV
$9.98M
Beat +102.85%
YoY:
-47.66%Next Earnings
Mar 3, 2027
EPS Est
Pro
Rev Est
Pro
Add to Watchlist
Select watchlists to add or remove XLO